Future Fertility
Future Fertility develops deep learning AI tools (VIOLET, MAGENTA, ROSE) that analyze oocyte images to predict egg quality and blastocyst development potential. The Toronto-based company sells on a B2B subscription basis to 300+ fertility clinics and egg banks across 35+ countries.
- Company typePrivate
- Founded2021
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Future Fertility does
Future Fertility is a Toronto-based fertility technology company that develops deep learning tools for non-invasive, image-based assessment of oocyte (egg) quality. Its core products, VIOLET, MAGENTA, and ROSE, analyze 2D microscope images of oocytes to predict blastocyst development potential, euploidy status, and live birth probability. VIOLET serves egg freezing patients, MAGENTA supports IVF/ICSI treatment planning, and ROSE is purpose-built for egg banks and donor egg programs. The company's models are trained on 650,000+ oocyte images with linked reproductive outcomes, the largest such dataset in the industry, and have been clinically validated against embryologist performance in peer-reviewed studies.
The company operates a B2B subscription model, distributing its tools exclusively through fertility clinics and egg banks rather than directly to consumers. An enterprise field sales team integrates VIOLET, MAGENTA, and ROSE into clinic laboratory workflows, with clinics receiving reports for their patients. Distribution has scaled to 300+ partner clinics across 35+ countries spanning North America, LATAM, Europe, the Middle East, and Asia-Pacific. Pricing is not publicly disclosed and is negotiated per clinic.
Future Fertility has raised $4.1M in a Series A round led by M Ventures (Merck KGaA's corporate venture arm) and Whitecap Venture Partners, with participation from Sandpiper Ventures, Gaingels, and Jolt VC. The company holds two granted US patents covering its AI methods, has produced 65+ peer-reviewed publications and abstracts, and was recognized at the 2025 World Fertility Awards. Planned near-term initiatives include US market entry via FDA 510(k) clearance and commercial expansion into Asia-Pacific, anchored by a partnership with Japan's Kato Ladies Clinic.
Future Fertility firmographics
Firmographics- Name
- Future Fertility
- Legal name
- Future Fertility
- Website
- https://futurefertility.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Future Fertility develops deep learning AI tools (VIOLET, MAGENTA, ROSE) that analyze oocyte images to predict egg quality and blastocyst development potential. The Toronto-based company sells on a B2B subscription basis to 300+ fertility clinics and egg banks across 35+ countries.
- Ownership category
- akta.pro rank
Future Fertility industry classification
Industry- Product category
- Reproductive Medicine AI Software
- NAICS
- Family Planning Centers (621410)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)
- akta.pro secondary industry
- Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)
Keywords
Where Future Fertility is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Future Fertility business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Clinic Subscription Services: Future Fertility provides AI-powered oocyte quality assessment tools to fertility clinics on a subscription basis. Clinics integrate the tools into their workflows and receive VIOLET, MAGENTA, and ROSE reports for their patients, generating recurring revenue from clinic subscriptions.
- FDA 510(k) Clearance Products: Planned FDA 510(k) clearance for additional products in the U.S. market, enabling expansion into new regulatory jurisdictions with corresponding revenue opportunities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Future Fertility product offering
Product offeringCore offering
Future Fertility develops and sells AI-powered, non-invasive oocyte (egg) quality assessment software that analyzes 2D microscope images of eggs to predict blastocyst development, euploidy, and live birth potential. Its core products VIOLET, MAGENTA, and ROSE are delivered to fertility clinics and egg banks on a subscription basis, with patient-facing reports surfaced through the MyFutureFertility platform.
Product overview
Future Fertility offers a portfolio of AI-powered, non-invasive oocyte (egg) quality assessment tools. The core products include VIOLET™ for egg freezing patients, MAGENTA™ for IVF patients, and ROSE™ for egg banks and donor egg programs. All three tools leverage deep learning models trained on the industry's largest dataset of 650,000+ oocyte images to deliver objective, personalized quality predictions. The MyFutureFertility platform provides patient-facing reports. These tools are currently deployed in over 300 clinics across 35+ countries and have been clinically validated with findings published in peer-reviewed journals.
Differentiator
Problem solved
Functional benefit
Brands
- VIOLET: AI-powered egg quality assessment tool for egg freezing patients, providing personalized predictions on fertilization and blastocyst development potential.
- MAGENTA
- ROSE
- MyFutureFertility
Products and services
- VIOLET AI-powered oocyte quality assessment tool for egg freezing patients that analyzes 2D images of each egg to provide personalized predictions on fertilization potential and blastocyst development, helping clinics counsel patients on future fertility treatment.
- MAGENTA AI-powered oocyte quality assessment tool for IVF and ICSI patients that delivers personalized quality scores per oocyte correlated with the likelihood of forming a high-quality blastocyst, enabling fertility clinics to optimize treatment planning and cycle outcomes.
- ROSE AI-powered oocyte quality assessment tool designed for egg banks and donor egg programs that uses clinically validated quality scores to optimize oocyte distribution, donor-recipient matching, and inventory management for donor populations.
- MyFutureFertility Patient insights platform that delivers Future Fertility's personalized VIOLET and MAGENTA egg quality reports to patients through partner fertility clinics, providing clear egg quality information to support fertility decision-making.
Quantifiable outcome
- 18% average relative improvement in blastocyst prediction accuracy compared to 50 embryologists from 15 IVF clinics
- +2 more outcomes
Companies that use Future Fertility
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Future Fertility technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Future Fertility partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Kato Ladies ClinicflagshipKato Ladies Clinic, Japan's leading IVF provider, partnered with Future Fertility to bring AI-powered oocyte quality assessment to the Japanese market. This partnership represents a key entry point for Asia-Pacific commercial expansion.
- 300+ Partner Clinics GloballycoreFuture Fertility has established a network of 300+ partner fertility clinics across 35+ countries that integrate their AI assessment tools. Clinics receive training, implementation support, and ongoing operational assistance to deliver VIOLET, MAGENTA, and ROSE reports to patients.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Future Fertility competitors and assessment
Company assessmentDirect peers
- AIVF: AIVF sells AI-powered clinical decision support to IVF clinics, including embryo quality assessment. It is the closest direct competitor to Future Fertility, targeting the same fertility-clinic B2B channel with AI tools that augment embryologist workflows.
- Fairtility: Fairtility provides AI-based embryo quality assessment (CHLOE) used in IVF labs. It competes with Future Fertility in the AI-for-reproductive-medicine category, focusing on embryo rather than oocyte assessment but addressing the same clinic customers.
- Alife Health: Alife Health builds AI applications for IVF clinics covering embryo ranking and clinical decision support. It directly overlaps with Future Fertility's positioning as an AI platform for the fertility clinic workflow.
Emerging players
- LifeWhisperer: LifeWhisperer applies AI to embryo and sperm image analysis to predict IVF success. It is a partial-overlap emerging player focused specifically on AI image-based fertility outcomes, similar to Future Fertility's image-based approach.
- Presagen: Presagen develops AI for women's health and fertility, including oocyte and embryo assessment. It is an adjacent emerging player with overlapping technology and target customers in the IVF and fertility space.
- Conceivable Life Sciences: Conceivable Life Sciences is an AI-driven IVF automation company developing robotics and AI for the IVF lab. It was co-recognized alongside Future Fertility at the 2025 World Fertility Awards and represents a next-generation emerging player in AI-enabled fertility treatment.
Broad incumbents
- Vitrolife: Vitrolife is a global IVF products company offering media, lab devices, and the EmbryoScope time-lapse system. It is a broad incumbent with deep clinic relationships and could bundle AI features into its existing platform, posing a competitive threat to Future Fertility.
- Genea Biomedx: Genea Biomedx develops and commercializes IVF lab instruments and automation, including the Geri time-lapse incubator. It is a broad incumbent with established clinic channels that overlap with Future Fertility's customer base.
- Hamilton Thorne: Hamilton Thorne provides ART/IVF lab equipment, software, and disposables used by fertility clinics worldwide. It is a broad incumbent in the IVF lab supply category that could expand into AI-enabled assessment tools adjacent to Future Fertility's offerings.
- Progyny: Progyny is a US fertility benefits platform that channels employer-covered patients to fertility clinics. While not a direct technology competitor, it sits upstream in the patient funnel and is a relevant comparable for the fertility-services ecosystem in which Future Fertility operates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Future Fertility social profiles
Digital presenceFuture Fertility financial estimates
Financial estimateRevenue estimate
Valuation estimate
Future Fertility leadership team
Management profileNumber of profiles
Profiles3 records
Future Fertility funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Future Fertility M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Future Fertility
What does Future Fertility do?
Future Fertility develops and sells AI-powered, non-invasive oocyte (egg) quality assessment software that analyzes 2D microscope images of eggs to predict blastocyst development, euploidy, and live birth potential. Its core products VIOLET, MAGENTA, and ROSE are delivered to fertility clinics and egg banks on a subscription basis, with patient-facing reports surfaced through the MyFutureFertility platform.
Is Future Fertility a public or private company?
Future Fertility is a private company. It is classified as venture growth investor backed and is currently operating.
When was Future Fertility founded?
Future Fertility was founded in 2021. It employs 11 to 50 people.
Where is Future Fertility based?
Future Fertility is headquartered in Toronto, Canada, in the North America region.
How does Future Fertility make money?
Two revenue lines are on record. Clinic Subscription Services are the primary driver. The others are FDA 510(k) Clearance Products.
Who are Future Fertility's main competitors?
Direct peers on record are AIVF, Fairtility and Alife Health. Emerging players are LifeWhisperer, Presagen and Conceivable Life Sciences. Broad incumbents are Vitrolife, Genea Biomedx, Hamilton Thorne and Progyny.
Does Future Fertility have an API?
No public API is recorded for Future Fertility.
What industry is Future Fertility in?
Future Fertility's product category is Reproductive Medicine AI Software. Its primary akta.pro industry code is HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation), with a secondary code of HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers. Its NAICS code is 621410 and its SIC code is 2835.